CTOs on the Move

Asher Bio

www.asherbio.com

 
Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Asher Bio raised $55M on 03/23/2021

Similar Companies

Elanco

Elanco Animal Health Incorporated is a prominent American pharmaceutical company focused on developing, manufacturing, and marketing medicines and vaccinations for pets and livestock. Established in 1954 as a division of Eli Lilly and Company, Elanco became an independent entity in 2018 and has since grown to be one of the largest independent animal health companies worldwide. The acquisition of Bayer Animal Health in 2020 significantly expanded its size and global reach. Elanco offers a wide range of products aimed at enhancing animal health and productivity. This includes pharmaceuticals and vaccines for livestock and companion animals, nutritional solutions to improve feed efficiency, and data analytics through its Elanco Knowledge Solutions division. The company serves a diverse customer base, including farmers, veterinarians, pet owners, and agricultural stakeholders, all dedicated to improving animal health and food quality. Elancos mission emphasizes the importance of food and companionship in enriching life, reflecting its commitment to animal welfare and innovation in the animal health sector.

FASgen

FASgen is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Acureon Pharmaceuticals

Acureon Pharmaceuticals is a Berwyn, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exicure

Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Celsis International Plc

Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas, rapid detection, analytical and